Testosterone Injections for Women: Doses & Risks

Key Takeaways: Injectable testosterone is not first-line therapy for women, but some clinicians prescribe low-dose injections (5-20 mg/week) when topical options fail or are impractical. The primary risks are supraphysiologic hormone spikes and virilization. Subcutaneous injection with an insulin syringe offers better dose control than intramuscular. Frequent monitoring is essential.

Why Injections Are Not First-Line for Women

Every major clinical guideline on testosterone therapy for women recommends transdermal delivery -- cream, gel, or patch -- as the starting point. The 2019 Global Consensus Position Statement is explicit: injectable testosterone formulations are not recommended for women because they produce supraphysiologic levels that increase virilization risk [1].

The reasoning is straightforward. Women need roughly one-tenth the testosterone dose that men do. The target range for most women on TRT is a total testosterone of 30-70 ng/dL, compared to 500-900 ng/dL for men. At these tiny doses, the pharmacokinetics of injectable testosterone work against you:

• Peak-and-trough cycling. Even low-dose injections create a spike in the first 24-48 hours followed by a decline. At female physiologic doses, these swings can push levels into the supraphysiologic range at the peak and below therapeutic range at the trough.
• Dosing precision. A 5 mg dose of testosterone cypionate 200 mg/mL is 0.025 mL -- a volume that is difficult to measure accurately even with an insulin syringe.
• No approved product. There is no FDA-approved injectable testosterone product dosed for women. All injectable use is off-label with male formulations.

Transdermal testosterone (cream or gel) avoids these problems. It delivers small, consistent amounts through the skin, producing stable blood levels without dramatic peaks [2]. This is why the Endocrine Society, the ISSWSH, and the International Menopause Society all recommend transdermal routes first [3][4].

When Clinicians Prescribe Injections Anyway

Despite the guidelines, some clinicians do prescribe low-dose injectable testosterone for women. Common scenarios include:

Topical Failure or Intolerance

Some women absorb transdermal testosterone poorly due to skin type, sweating, or the formulation itself. If blood work shows persistently low testosterone levels despite proper cream or gel use and dose escalation, a switch to injectable delivery may be warranted.

Transfer Concerns

Women with young children or partners who are pregnant face real risks of testosterone transfer through skin contact. Injections eliminate this concern entirely because the testosterone enters the bloodstream directly.

Access and Cost

Compounded testosterone cream can cost $30-80/month depending on the pharmacy and insurance coverage. A single 10 mL vial of testosterone cypionate 200 mg/mL costs $30-70 and lasts months at female doses, making injections the least expensive option by a wide margin.

Patient Preference

Some women prefer the certainty of a measured injection over the variability of topical absorption. Knowing exactly how many milligrams entered the body appeals to patients who want tight control.

Compounding Pharmacy Unavailability

Not all regions have compounding pharmacies that produce low-concentration testosterone cream for women. Standard commercially available testosterone products are dosed for men. Injectable testosterone from a standard pharmacy is universally available.

Typical Doses for Women

Female injectable testosterone doses are dramatically lower than male doses. Here is what the clinical literature and prescribing practice support:

Parameter	Female dose	Male dose (comparison)
Weekly dose	5-20 mg	100-200 mg
Concentration used	200 mg/mL (same vial)	200 mg/mL
Injection volume	0.025-0.1 mL	0.5-1.0 mL
Target total T	30-70 ng/dL	500-900 ng/dL
Injection frequency	1-2x per week	1-2x per week
Typical ester	Cypionate or enanthate	Cypionate or enanthate

Starting Protocol

Most clinicians who prescribe injectable testosterone for women follow this approach:

1. Start low: 5 mg per week (0.025 mL of 200 mg/mL)
2. Lab check at 4-6 weeks: Total testosterone, free testosterone, SHBG, estradiol, CBC
3. Draw labs at trough: The morning of the next injection, before injecting
4. Titrate slowly: Increase by 2.5-5 mg increments if levels remain below target and symptoms persist
5. Ceiling: Most women should not exceed 20 mg/week. Doses above this almost always produce supraphysiologic levels

Some clinicians prescribe even lower starting doses of 2-4 mg per week, particularly for smaller women or those who have shown sensitivity to androgens.

Split Dosing

Because of the peak-and-trough problem, many clinicians recommend splitting the weekly dose into two injections. A woman prescribed 10 mg/week would inject 5 mg every 3.5 days. This produces more stable blood levels and reduces the peak, lowering virilization risk.

Injection Technique for Women

Women using injectable testosterone typically use subcutaneous (SubQ) injection rather than intramuscular (IM). Research confirms that subcutaneous testosterone delivery is effective and produces comparable blood levels to IM injection, with less pain and easier self-administration [5].

Equipment

• Syringe: Insulin syringe (0.5 mL or 1 mL) with a 27-30 gauge needle
• Needle length: 1/2 inch (sufficient for subcutaneous injection)
• Alcohol swabs for site cleaning

The insulin syringe is critical. Standard 3 mL syringes cannot accurately measure the tiny volumes women need. A 0.5 mL insulin syringe with 50-unit markings allows you to measure 0.025 mL (2.5 units) with reasonable precision.

Injection Sites

• Abdomen: 1-2 inches from the navel, alternating sides. Pinch a fold of skin and inject at a 45-degree angle.
• Outer thigh: Upper outer quadrant. Same pinch-and-inject technique.
• Back of the upper arm: If someone else can administer the injection.

Rotate sites to prevent lipohypertrophy (thickening of fat tissue at the injection site).

Step-by-Step Process

1. Wash hands thoroughly
2. Draw the prescribed volume from the vial using the insulin syringe
3. Clean the injection site with an alcohol swab and let it dry
4. Pinch a fold of skin at the site
5. Insert the needle at a 45-degree angle
6. Inject slowly and steadily
7. Release the skin fold, withdraw the needle, and apply light pressure with a cotton ball

Virilization Risk: The Central Concern

Virilization is the development of male physical characteristics. It is the primary safety concern with testosterone therapy in women, and injectable delivery carries the highest risk among all routes because of the supraphysiologic peaks it creates [6].

Signs of Virilization (In Order of Onset)

Sign	Typically appears	Reversible?
Acne	Weeks 2-6	Yes, with dose reduction
Oily skin	Weeks 2-6	Yes
Increased body hair	Months 1-3	Partially (slows but may not fully reverse)
Facial hair (chin, upper lip)	Months 2-6	Partially
Scalp hair thinning	Months 3-12	Variable
Voice deepening	Months 3-12	Often irreversible
Clitoral enlargement	Months 6+	Often irreversible

The early signs (acne, oily skin) are warning signals. If they appear, check blood work immediately. Any dose producing a total testosterone above 70 ng/dL at trough should be reduced. If voice changes or clitoral enlargement develop, discontinue injectable testosterone and consider switching to a lower-dose transdermal formulation.

Why Injections Carry More Risk

A woman injecting 10 mg of testosterone cypionate may see her levels spike to 80-120 ng/dL within 24-48 hours, then decline to 30-40 ng/dL by day 7. Those peak levels are supraphysiologic for a woman and drive androgenic side effects, even though the trough levels look normal.

Cream or gel, by contrast, produces a much flatter curve. A woman applying 5 mg of testosterone cream daily typically sees levels in the 40-60 ng/dL range with minimal fluctuation. This is why topical delivery has a better safety profile at equivalent weekly doses.

Risk Reduction Strategies

• Split doses into 2 injections per week to flatten peaks
• Use the lowest effective dose -- start at 5 mg/week and titrate slowly
• Monitor aggressively -- blood work at 4-6 weeks, then every 3 months for the first year
• Check trough AND peak -- draw labs at trough (pre-injection) and 24-48 hours post-injection to capture the full picture
• Keep a symptom journal tracking skin changes, hair, voice, and mood
• Set a hard ceiling -- most clinicians will not exceed 20 mg/week regardless of symptoms

Injections vs Cream vs Gel vs Pellets

This comparison focuses specifically on how each delivery method performs for women. The considerations are different from men because the margin between therapeutic and supraphysiologic dosing is much narrower.

Factor	Injections	Cream	Gel	Pellets
Dose control	Moderate -- precise volume but peak/trough	Excellent -- daily titration	Excellent -- daily titration	Poor -- fixed once inserted
Blood level stability	Low -- peaks and troughs	High -- steady levels	High -- steady levels	High initially, then declining
Virilization risk	Higher (peaks)	Lower	Lower	Moderate (cannot reduce once placed)
Reversibility	Stop injecting	Stop applying	Stop applying	Must wait 3-4 months to clear
Transfer risk	None	Moderate	Moderate	None
Convenience	1-2x/week injection	Daily application	Daily application	Every 3-4 months
Cost (monthly)	$5-15	$30-80	$30-80	$75-170 (amortized)
Access	Any pharmacy	Compounding pharmacy	Compounding or commercial	Specialized clinic
Self-administrable	Yes (SubQ)	Yes	Yes	No (office procedure)
Guideline recommended	No -- off-label	Yes -- first-line	Yes -- first-line	Not specifically

Bottom Line

Testosterone cream remains the best starting point for most women. It offers the finest dose control, the most stable blood levels, and the easiest path to dose adjustment if side effects emerge. Testosterone gel is a close alternative with faster drying time. Pellets suit women who want a hands-off approach and have already established their optimal dose with a titratable method. Injections are a reasonable fallback when topical delivery fails, but they require more vigilant monitoring.

For a detailed comparison of dosing across all delivery methods, see our Women's Testosterone Dosage Guide.

Monitoring Protocol on Injectable Testosterone

Monitoring is more intensive for injectable testosterone than for topical formulations. Because of the peak-and-trough pattern, a single blood draw does not tell the whole story.

Baseline Labs (Before Starting)

• Total testosterone and free testosterone
• SHBG (sex hormone-binding globulin)
• Estradiol
• DHEA-S
• CBC (complete blood count) -- testosterone can increase hemoglobin and hematocrit
• Lipid panel
• Liver function (ALT, AST)

First Follow-Up (4-6 Weeks)

• Total and free testosterone at trough (morning of injection day, before injecting)
• Optionally: total testosterone at peak (24-48 hours after injection) to assess the swing
• Clinical assessment: skin changes, hair, mood, energy, libido
• CBC if dose is above 10 mg/week

Ongoing Monitoring

• Every 3 months for the first year: testosterone (trough), clinical symptom check
• Every 6-12 months after stabilization: full panel including CBC, lipids, liver function
• Annual: breast exam, pelvic exam per standard care

Red Flags That Warrant Immediate Action

• Total testosterone above 70 ng/dL at trough
• Total testosterone above 150 ng/dL at peak
• Hematocrit above 48% (women's upper limit)
• New acne, facial hair, or voice changes
• Mood changes: irritability, aggression, or anxiety

If any red flag appears, reduce the dose by 50% or switch to transdermal delivery and recheck in 4 weeks [7].

Who Should Not Use Injectable Testosterone

Injectable testosterone is contraindicated or used with extreme caution in these situations:

• Pregnancy or planning pregnancy -- testosterone is teratogenic and causes virilization of a female fetus
• Androgen-sensitive cancers -- hormone receptor-positive breast cancer (discuss with oncologist)
• Polycystic ovary syndrome (PCOS) -- already elevated androgens; adding exogenous testosterone worsens symptoms
• Severe acne or hirsutism -- indicates androgen sensitivity; topical delivery at minimal doses may be tolerable, but injections likely are not
• Liver disease -- though injectable testosterone bypasses first-pass liver metabolism, monitoring is still required
• Erythrocytosis -- pre-existing elevated red blood cell counts (hematocrit above 48%)

Women with a history of androgen sensitivity (severe acne during puberty, hirsutism, or PCOS-like symptoms) should avoid injections and use the lowest-dose transdermal option if testosterone therapy is pursued.

Practical Considerations

Compounding for Lower Concentrations

Some compounding pharmacies will prepare testosterone cypionate at lower concentrations (e.g., 50 mg/mL or 100 mg/mL) specifically for women. This makes dosing easier and more accurate:

• 5 mg dose from 50 mg/mL = 0.1 mL (much easier to measure than 0.025 mL from 200 mg/mL)
• 10 mg dose from 100 mg/mL = 0.1 mL

If your clinician prescribes injectable testosterone, ask about compounded lower-concentration options.

Storage and Handling

• Store testosterone cypionate at room temperature (68-77 F)
• The oil may crystallize in cold temperatures -- warm the vial in your hands for a few minutes before drawing
• Multi-dose vials are typically good for 28 days after first puncture (check the label)
• A 10 mL vial of 200 mg/mL contains 2,000 mg total -- at 10 mg/week, this lasts approximately 200 weeks (nearly 4 years), well beyond the expiration date. A 1 mL vial is more practical for women.

Insurance and Prescriptions

Injectable testosterone for women is entirely off-label. Some insurance plans will cover testosterone cypionate with a diagnosis code for hypoactive sexual desire disorder (F52.0) or other hormone deficiency. Others will not. The out-of-pocket cost is low enough ($30-70 for a vial lasting many months) that insurance denial is usually not a financial barrier.

When to Consider Switching Off Injections

Even women who start on injections successfully may benefit from transitioning to transdermal delivery once their optimal dose is established. Consider switching if:

• Virilization signs appear despite dose reduction
• Blood work shows persistent peak-trough swings greater than 2x
• The convenience advantage diminishes (many women find daily cream application becomes routine)
• A compounding pharmacy becomes accessible

The reverse transition -- from topical to injectable -- is appropriate when topical delivery consistently fails to achieve therapeutic levels despite proper application technique and adequate dosing.

For a comprehensive overview of side effects across all delivery methods, including long-term safety data, see our dedicated guide. Women considering TRT for the first time should also review our guide to finding a women's HRT clinic.

References

1. Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019;104(10):4660-4666. PMID: 31488288

2. Fooladi E, Reuter SE, Bell RJ, Robinson PJ, Davis SR. Pharmacokinetics of a transdermal testosterone cream in healthy postmenopausal women. Menopause. 2015;22(1):44-49. PMID: 24845394

3. Wierman ME, Arlt W, Basson R, et al. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(10):3489-3510. PMID: 25279570

4. Parish SJ, Simon JA, Davis SR, et al. International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. Climacteric. 2021;24(6):533-550. PMID: 33792440

5. Spratt DI, Stewart II, Engel S, et al. Subcutaneous Injection of Testosterone Is an Effective and Preferred Alternative to Intramuscular Injection: Demonstration in Female-to-Male Transgender Patients. J Clin Endocrinol Metab. 2017;102(7):2349-2355. PMID: 28379417

6. Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019;7(10):754-766. PMID: 31353194

7. Bachmann G, Bancroft J, Braunstein G, et al. Testosterone therapy in women: a review. Int J Impot Res. 2005;17(5):399-408. PMID: 15889125